How the 10 largest publicly traded biopharmaceutical companies compare to 10 of the largest publicly traded nonbiopharmaceutical companies in the area of gender diversity among executive leadership.

How can we address challenges that have plagued our past, such as egregious drug price increases, corruption, collusion, deception, and unethical marketing practices?

An inside look into how this fledgling biopharma has raised over $150 million and enlisted two high-profile CEOs from one of the hottest VC firms around, all in less than two years.

With President Trump’s recently announced focus on reducing the price of prescription drugs, perhaps it is time branded biopharmaceutical companies consider competing in other areas beyond just biosimilars (i.e., generic biologics).

Successful drug discovery and development requires a passionate commitment, something that can only be displayed during the breakout sessions at the J.P. Morgan annual healthcare conference.

While some continue to focus on the lack of gender diversity at the annual J.P. Morgan healthcare conference, GSK’s CEO, Emma Walmsley, notes that supporting diversity means doing more than just focusing on the “gender agenda.”

The annual J.P. Morgan and Biotech Showcase conferences not only provide great networking opportunities, they expose you to interesting and cutting-edge companies to keep on your radar.

An idea for how the biopharmaceutical and life science industries could make a bigger difference during the annual January JPM invasion of San Francisco.

When Joseph Papa took over Valeant Pharmaceuticals in May 2016, the company was in turmoil. We catch up with Papa and see how he’s coming with what he calls “the turnaround opportunity of a lifetime.”